RxDoctor Payments Data

James Rice, MD

Cardiovascular Disease · Springfield, MONPI 1417991894

Payments from drug & device makers

$11,552in general payments, 2019–2025

Across 760 payments — averaging $15.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Pfizer$1K
  • Amgen$1K
  • Boehringer Ingelheim$937
  • Johnson & Johnson$937
  • Novartis$814
  • plus $5K from 39 others

What the payments were for

  • Food & beverage$11,42199%
  • Education$1301%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,552 in reported general payments places this provider in the 70th percentile of 391 cardiovascular disease providers in Missouri.

See all cardiovascular disease providers in Missouri

Medicare billing

Part B allowed, 2024
$192,902
Medicare patients
1,679
Services billed
4,247

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,617$1,410,397
EntrestoSacubitril/Valsartan513$462,659
XareltoRivaroxaban398$334,395
Repatha SureclickEvolocumab392$263,586
FarxigaDapagliflozin Propanediol180$129,479
Repatha SyringeEvolocumab134$82,068
JardianceEmpagliflozin86$68,370
Praluent PenAlirocumab81$51,821
Ranolazine ErRanolazine250$27,605
WegovySemaglutide19$25,437
BrilintaTicagrelor24$18,402
Metoprolol Succinate1,707$17,548
NexletolBempedoic Acid23$13,723
VascepaIcosapent Ethyl29$13,676
Rosuvastatin Calcium1,193$13,453

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,339$1,410,3971,617 claims
NovartisEntresto$814$462,659513 claims
Johnson & JohnsonXarelto$937$334,395398 claims
AstraZenecaFarxiga, Brilinta$1,397$147,881204 claims
Boehringer IngelheimJardiance$937$68,37086 claims
Esperion Therapeutics, Inc.Nexletol, Nexlizet$29$26,34555 claims
Novo NordiskWegovy$462$25,43719 claims
Sanofi-aventis U.S. LLCMultaq$156$12,53816 claims
Arbor Pharmaceuticals, Inc.Edarbi$29$3,12512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 391 cardiovascular disease providers in Missouri.

Other cardiovascular disease in Springfield

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →